This case-based activity is designed to provide learners with practical guidance on management of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) and highlight areas of uncertainty where there may be a range of acceptable treatment approaches.

This webinar reviews principles for effectively treating oropharyngeal cancers with radiation therapy.

This course is designed to provide clinicians in practice and trainees with a comprehensive review and update of the clinical practice parameters across most major sub-disciplines of radiation oncology, including sarcomas, pediatrics and lymphomas, and the role of radiotherapy in the multidiscipl

Patients with head and neck cancer require specialized and multi-modality support during treatment. Providers may not be informed of the most up-to-date techniques to prevent and treat head and neck cancer radiation-related toxicity.

The clinical practice regarding feeding tube use in patients undergoing radiotherapy for head and neck cancer varies greatly. Ongoing research advances, as well as indications for feeding tube use in contemporary practices are required to provide optimal care.

The field of cancer is a rapidly evolving field with new treatment approaches moving to clinic on a daily basis. Radiation Oncology is no different. It is extremely difficult for a practicing clinician to stay abreast of new developments in cancer care.

The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

Recently, there have been exciting advances in the treatment of relapsed/refractory (R/R) lymphomas. Historically, the standard-of-care included salvage chemotherapy followed by autologous stem cell transplantation (ASCT). Today, many other salvage options are available.

Head and neck cancer patients experience severe acute and late toxicity from radiation therapy. This activity explores ways to prevent, mitigate and treat toxicities from treatment. The first presenter discusses dosimetric and planning parameters to reduce toxicity.

Management of unknown primary head and neck squamous cell carcinomas has evolved as the incidence of p16 positive disease among head and neck cancer patients has increased.

Pages

Subscribe to RSS - Head and Neck